Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Dose, Open-Label, Randomized, Two-Way Crossover Pivotal Study to Assess the Bioequivalence of a New ULTRACET ER Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition

NCT01778075 is registered in ClinicalTrials.gov with Janssen Korea, Ltd., Korea as lead sponsor.

NCT NCT01778075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01778075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Dose, Open-Label, Randomized, Two-Way Crossover Pivotal Study to Assess the Bioequivalence of a New ULTRACET ER Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition
Lead sponsor
Janssen Korea, Ltd., Korea
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2012
Completion date
February 28, 2013
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy